Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 77.15M
March 31, 2026 76.60M
December 31, 2025 76.57M
September 30, 2025 77.77M
June 30, 2025 82.82M
March 31, 2025 79.46M
December 31, 2024 80.76M
September 30, 2024 82.68M
June 30, 2024 82.82M
March 31, 2024 82.56M
December 31, 2023 82.50M
September 30, 2023 82.33M
June 30, 2023 82.15M
March 31, 2023 81.93M
December 31, 2022 81.72M
September 30, 2022 81.65M
June 30, 2022 81.53M
March 31, 2022 81.29M
December 31, 2021 81.55M
September 30, 2021 81.40M
June 30, 2021 52.96M
March 31, 2021 52.86M
December 31, 2020 52.79M
September 30, 2020 52.78M
June 30, 2020 52.63M
Date Value
March 31, 2020 52.51M
December 31, 2019 53.62M
September 30, 2019 53.64M
June 30, 2019 54.08M
March 31, 2019 53.98M
December 31, 2018 53.97M
September 30, 2018 54.44M
June 30, 2018 54.33M
March 31, 2018 53.79M
December 31, 2017 54.08M
September 30, 2017 54.15M
June 30, 2017 54.04M
March 31, 2017 53.78M
December 31, 2016 54.53M
September 30, 2016 55.83M
June 30, 2016 55.46M
March 31, 2016 55.07M
December 31, 2015 54.96M
September 30, 2015 57.23M
June 30, 2015 59.87M
March 31, 2015 60.58M
December 31, 2014 60.11M
September 30, 2014 61.57M
June 30, 2014 61.90M
March 31, 2014 62.02M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
IQVIA Holdings, Inc. 164.60M
Medpace Holdings, Inc. 27.84M
Proteome Sciences Plc --
Champions Oncology, Inc. 13.92M
Avantor, Inc. 676.50M